The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY.
Sorbonne Université ACTION study group INSERM UMR_S 1166 Institut de Cardiologie Hôpital Pitié-Salpêtrière (AP-HP) Paris France.
J Am Heart Assoc. 2020 Apr 7;9(7):e014611. doi: 10.1161/JAHA.119.014611. Epub 2020 Mar 30.
Background Women have been associated with higher rates of recurrent events after percutaneous coronary intervention than men, possibly attributable to advanced age at presentation and greater comorbidities. These factors also put women at higher risk of bleeding, which may influence therapeutic strategies and clinical outcomes. Methods and Results We performed a patient-level pooled analysis of 4 postapproval registries to evaluate sex-related differences in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention. HBR required fulfillment of at least 1 major or 2 minor criteria of the Academic Research Consortium definition. Outcomes of interest were major bleeding and major adverse cardiac events (composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis). Of the total 10 502 patients, 2832 (27.0%) were women. The prevalence of HBR was higher in women compared with men (29.0% versus 20.5%, <0.0001). Women at HBR were older and had more comorbidities, while men at HBR were more often smokers, with prior myocardial infarction and more complex coronary lesions. At 4 years, women at HBR had significantly higher major bleeding compared with men at HBR (10.8% versus 6.2%, <0.0001); however, this difference was attenuated after multivariable adjustment (hazard ratio, 0.92; 95% CI, 0.41-2.08). Major adverse cardiac event rates between groups were similar (12.2% versus 12.6%, =0.82) and remained consistent after adjustment (hazard ratio, 0.64; 95% CI, 0.32-1.28). Conclusions The prevalence of HBR was higher in women compared with men, with considerable differences in the distribution of criteria. Women at HBR experienced higher rates of major bleeding but similar major adverse cardiac event rates compared with men at HBR at 4 years.
与男性相比,女性经皮冠状动脉介入治疗后的复发事件发生率更高,这可能归因于发病时年龄较大和合并症较多。这些因素也使女性出血风险更高,这可能会影响治疗策略和临床结局。
我们对 4 项批准后注册研究进行了患者水平的汇总分析,以评估高出血风险(HBR)行经皮冠状动脉介入治疗的患者的性别差异。HBR 需要满足学术研究联合会(ARC)定义的至少 1 项主要标准或 2 项次要标准。主要观察终点为大出血和主要不良心脏事件(包括心脏死亡、心肌梗死或确定/可能的支架血栓形成)。在总共 10502 例患者中,2832 例(27.0%)为女性。与男性相比,女性的 HBR 发生率更高(29.0%比 20.5%,<0.0001)。HBR 女性年龄较大,合并症较多,而 HBR 男性更多为吸烟者,既往有心肌梗死且冠状动脉病变更为复杂。4 年时,HBR 女性的大出血发生率明显高于 HBR 男性(10.8%比 6.2%,<0.0001);然而,经多变量调整后,这种差异减弱(风险比,0.92;95%可信区间,0.41-2.08)。两组之间的主要不良心脏事件发生率相似(12.2%比 12.6%,=0.82),调整后仍保持一致(风险比,0.64;95%可信区间,0.32-1.28)。
与男性相比,女性 HBR 的发生率更高,且标准的分布存在较大差异。HBR 女性的大出血发生率较高,但与 HBR 男性相比,4 年时的主要不良心脏事件发生率相似。